Clinical report: Data from Gilead, KalVista, Takeda, Synlogic and AN2

It’s the end of the line for Gilead’s magrolimab in hematological cancers, but the repeated failures of CD47’s most advanced program might not derail the entire class.

Last week,  Gilead Sciences Inc. (NASDAQ:GILD) reported that FDA placed a clinical hold on all studies of magrolimab in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after an independent Data Monitoring Committee reported futility and an increased risk of death, primarily due to infections and respiratory failure in the Phase III ENHANCE-3 study...